Why Some ASX Gold Miners May Still Be Undervalued
"Gold is money. Everything else is credit."- J.P. Morgan Gold has been on a rampage for some years now, especially in recent months, pushing through all-time highs as investors seek safety from inflation, geopolitical uncertainty, and weakening currencies. Yet while bullion shines, the response from Australian gold…
There's hope for equity markets in 2025
When the market is crashing as hard as it has been doing in the last few trading sessions, not many investors want to look too far out or think about upside scenarios in the medium term. And that is probably the case this time around as well with…
Weebit Nano (ASX:WBT)
On 2 January 2025, Weebit Nano (ASX:WBT) announced the third license deal for its ReRAM technology, in this case with American chip manufacturer ON Semi (NASDAQ:ON). ON Semi is a so-called Integrated Device Manufacturer (IDM), which means it designs and manufactures its chips in-house. By contrast, fabless chip companies, such as Apple…
It's been a rough few years for Small and Mid Cap Stocks!
The Bear Market in Small Caps is now 30 months old. Ever since Central Banks around the world started raising interest rates in early 2022, large parts of the global equity markets have struggled, Small and Mid Cap stocks in particular. However, Large…
Australian interest rates influenced by US inflation trend
On 13 June, US consumer prices (CPI) came in lower than expected for the month of May. The market was expecting 3.4% inflation in May, where the actual number came in at 3.3%. It might not seem like a big difference, but we believe it is significant…
Dimerix (ASX:DXB) did it again
ASX-listed kidney disease drug developer Dimerix (ASX: DXB) is well positioned to bring its DMX-200 drug to market for Focal Segmental Glomerulosclerosis (FSGS). The drug is in a Phase 3 trial, which has shown solid interim results. The company secured its inaugural license deal in October 2023 with Advanz Pharma,…
5 ASX Health Stocks
Stuart Roberts from Stocks Down Under discussed the potential promise of biotech, sharing his perspectives about the industry's future amidst changing interest rates. He compares the current market situation to 1994 when the introduction of interest rate tightenings led to bear markets for many pre-revenue stocks. However, despite ongoing mildly bearish…
Should you buy Rio Tinto shares? This is one of the most asked questions by investors, given how prominent a company it is. It is only behind CBA (ASX:CBA) and BHP (ASX:BHP), sitting at a market capitalisation of ~$160bn as of mid-March 2024.The first few months of 2024 have been tough for Rio Tinto (ASX:RIO).…
ASX gold stocks should be in focus right now!
Our own Stuart Roberts identifies the ongoing merit of investing in gold, seeing it as an effective insurance policy against global instability. Stuart suggests setting aside about 10% of your assets in ASX gold stocks. However, he recognises a generational shift towards investments in Bitcoin and…
Where will gold prices go? It is a question investors are asking all the time, but particularly in recent years given that global geopolitical instability and macroeconomic turbulence are its two best mates. But where to now from here? Will investors buying gold end up buying high and selling low, or will they still reap…
